Document:

<Page>

EXHIBIT 10.12

                            REVOLVING LINE OF CREDIT
                                    AGREEMENT

THIS REVOLVING LINE OF CREDIT AND SECURITY AGREEMENT (this "Agreement") is dated
and effective as of December 28, 2001 by and between TRANSGENOMIC, INC., a
corporation organized under the laws of the State of Delaware U.S.A. and with
its principal place of business in Omaha, Nebraska U.S.A. (the "Lender"), and
GENODYSSEE S.A., a societe anonyme organized under the laws of France, with a
share capital of 65,122 euros, having its registered office at Parc Affaires
Technopolis, 3, avenue du Canada, BP 810 Les Ulis, 91974 Courtaboeuf, France and
registered with the REGISTRE DU COMMERCE ET DES SOCIETES of Evry under number
424 796 548 ("the Borrower"). The Lender and the Borrower are sometimes
collectively referred to herein as the "parties" and individually as a "party."

                                    PREAMBLE

WHEREAS, the Lender and the Borrower have entered into a Services Provider
Agreement, dated as of the date hereof (the "Services Agreement"), pursuant to
which Borrower will provide certain genetic discovery analysis services to
clients of the Lender requiring such services and Lender will commit certain
sales and support resources to obtaining clients requiring such services; and

WHEREAS, in order to provide additional working capital to Borrower during the
initial term of the Services Agreement, the Lender has agreed to make available
to the Borrower, on a revolving basis, a line of credit in an amount of up to
One Million U.S. Dollars (US $1,000,000) (the "Loan"), subject to the terms and
conditions set forth herein, which line of credit will evidenced by a promissory
note in the form attached hereto as Exhibit A (the "Note"); and

WHEREAS, the parties desire to set forth certain terms and conditions relating
to the Loan;

NOW, THEREFORE, in consideration of the mutual covenants, promises,
representations and warranties set forth herein, the parties agree as follows:

                                   ARTICLE II

                                   DEFINITIONS

All capitalized terms used in this Agreement shall have the following meanings
(such meanings to be equally applicable to both the singular and the plural
forms of the terms defined):

"ADVANCES" shall have the meaning set forth in Section 2.01.

"AGREEMENT" shall mean this Revolving Line of Credit Agreement, as the same may
be amended or otherwise modified from time to time.

"BORROWING BASE" shall mean the total future Revenue Splits to which the
Borrower shall be entitled under the Services Agreement resulting from all
remaining contractual payments to be made (including any amounts in excess of
minimum contractual payments that the parties agree are more likely than not to
be made) under Customer Agreements which the Borrower is servicing pursuant to
the Services Agreement in existence on the date the Borrowing Base is
calculated; provided, that Revenue Splits from any Customer Agreement for which
any contractual payments are more than 30 days past due shall be excluded from
the Borrowing Base. The Borrowing Base shall be calculated as of the last
Business Day of each calendar quarter during the term of this Agreement.

"BUSINESS DAY" shall mean a day other than a Saturday, Sunday or other day on
which commercial banks are authorized or required to close under the laws of the
United States of America or the Republic of France.

"CUSTOMER AGREEMENTS" shall mean those agreements entered into from time to time
with customers by the Lender or the Borrower (as the case may be) pursuant to
the Services Agreement.

"DEFAULT" shall mean any of the events specified in Section 7.01, without giving
effect to any requirement for the giving of notice, for the lapse of time, or
both, or for the happening of any other condition, event or

                                       1
<Page>

act.

"EVENT OF DEFAULT" shall mean any of the events specified in Section 7.01,
provided that any requirement for the giving of notice, the lapse of time, or
both, or for the happening of any further condition, event or act has occurred
or has been satisfied.

"GOVERNMENTAL AUTHORITY" shall mean any government (whether the located within
or outside the United States or France) or any department, agency, division or
instrumentality thereof.

"LAW" shall mean any statute, rule, regulation, order, judgment, award or decree
of any Governmental Authority.

"MATURITY DATE" shall have the meaning set forth in Section 4.02.

"PAYMENT DATE" shall mean (i) the last Business Day of each calendar quarter
during the term hereof and (ii) any date upon which some or all of the
Outstanding Principal Balance of the Loan is due and payable hereunder under
Section 4.02 hereof.

"PERSON" shall mean and include an individual, a partnership, a corporation, a
trust, an unincorporated association, a joint venture or any other entity or a
government or any agency or political subdivision thereof.

     "OUTSTANDING PRINCIPAL BALANCE" shall mean the aggregate amount of all
Advances made by the Lender to the Borrower hereunder, less all repayments
thereof.

     "REVENUE SPLIT" shall mean that portion of the gross revenues (calculated
on a cash basis in accordance with accounting principles generally accepted in
the United States of America) received under a Customer Agreement to which
either the Lender or the Borrower shall be entitled pursuant to the Services
Agreement.

     "SERVICES AGREEMENT" shall mean the agreement between the Lender and the
Borrower, dated as of the date hereof, pursuant to which Borrower will provide
certain genetic discovery analysis services to third parties that enter into
Customer Agreements, Lender will commit certain sales and support resources to
obtaining customers requiring such services and the Lender and Borrower shall
share in the gross revenues generated by the Customer Agreements.

All monetary amounts expressed herein are stated in terms of U.S. Dollars.

                                   ARTICLE III

                                    THE LOAN

SECTION 3.01. LOAN ADVANCES.

(a) The Lender shall make advances to the Borrower (each an "Advance") from time
    to time during the term hereof and ending on the Maturity Date (or such
    earlier time specified in Section 4.02(a) hereof); in such amounts as may be
    requested by the Borrower in accordance with the provisions hereof;
    provided, however, that the Outstanding Principal Amount at any time shall
    not exceed the lesser of (i) One Million and No/100 Dollars ($1,000,000.00)
    or (ii) 25% of the Borrowing Base (collectively, the "Loan"). The Loan will
    be evidenced by the Note.

(b) All requests for Advances shall be made by the Borrower to the Lender in
    writing (in such form as is reasonably satisfactory to the Lender) or by
    telephone request (which shall be promptly confirmed in writing) which
    specifies the amount of the Advance to be made and the date the proceeds of
    the Advance are requested to be made available to the Borrower (a "Loan
    Request"). No Loan Request will be made for less than $50,000 or, if less,
    the aggregate amount of the unused the Lender's

                                       2
<Page>

    commitment hereunder, and all Loan Requests will be made for Advances that
    are an integer multiple of $50,000 (plus such unused amount).

(c) A Loan Request received by the Lender on a day that is not a Business Day or
    that is received by Lender after 12:00 noon, Omaha, Nebraska U.S.A. time, on
    a Business Day shall be treated as having been received by the Lender on the
    first following Business Day. There may not be more than one Advance made on
    any one day. The Lender shall not incur liability to the Borrower for
    treating any such request as a Loan Request if the Lender believes in good
    faith that the Person making the request is an authorized officer of the
    Borrowing.

(d) Advances under the Line of Credit shall be made by direct wire transfer of
    funds from the Lender to an account designated by Borrower in writing to
    Lender.

SECTION 3.02. USE OF PROCEEDS. The Loan shall be applied by the Borrower for
     working capital purposes.

                                   ARTICLE IV

                                    INTEREST

SECTION 4.01. INTEREST RATE. The Borrower shall pay interest on the Outstanding
     Principal Balance at the rate of 5% per annum from the date of issuance
     thereof to and including the date of repayment.

SECTION 4.02. COMPUTATION. Interest on the Advances shall be computed on the
     basis of a year deemed to consist of 365 days and paid for the actual
     number of days elapsed.

                                   ARTICLE V

                                    PAYMENTS

SECTION 5.01. INTEREST PAYMENTS. All accrued and unpaid interest on the
     Outstanding Principal Balance will be payable, without demand of the
     Lender, on each Payment Date, whether or not the Borrower is required to
     repay any portion of the Outstanding Principal Balance on such Payment
     Date.

SECTION 5.02. PRINCIPAL PAYMENTS.

(a) The Outstanding Principal Balance shall be due and payable in full, without
    demand by the Lender, immediately upon 3:00 p.m. GMT on December 31, 2004
    (the "Maturity Date"). In addition, in the event of the early termination of
    the Services Agreement pursuant to the terms thereof, no additional advances
    will be made by the Lender to the Borrower under this Agreement and the
    Outstanding Principal Balance shall be due and payable in full on such date
    prior to the Maturity Date as the Lender and the Borrower shall negotiate in
    good faith, but which in no event shall be more than 180 days after the
    termination of the Services Agreement.

(b) On each Payment Date on which the full Outstanding Principal Balance is not
    required to be repaid, that portion, if any, of the Outstanding Principal
    Balance that exceeds the Borrowing Base calculated as of such Principal
    Payment Date shall be due and payable in full, without demand by the Lender.
    The Borrower will provide the Lender with a calculation of the Borrowing
    Base (in a form satisfactory to the Lender) no less than 10 Business Days
    prior to each such Principal Payment Date. Unless the Lender objects, in
    writing, to the Borrower's calculation of the Borrowing Base (which

                                       3
<Page>

    objection, if any, must be delivered to the Borrower not less than three
    Business Days prior to the relevant Principal Payment Date), the Borrower's
    calculation of the Borrowing Base shall be deemed to be agreed to by the
    Lender. If the Lender objects to the Borrower's calculation of the Borrowing
    Base, it shall notify the Borrower thereof and the parties agree to
    negotiate the dispute in good faith. No additional Advances shall be made by
    Lender hereunder until the parties resolve any such dispute by arbitration
    as provided in Section 8.06(b) hereof.

SECTION 5.03. MANNER OF PAYMENTS. All payments of principal and interest on the
    Loan to be made by the Borrower shall be by direct wire transfer of
    immediately available funds to such accounts as shall be designated by the
    Lender from time to time. All such payments shall be denominated in U.S.
    dollars and shall be made on or before the date when due, without deduction,
    setoff or counterclaim by the Borrower.

SECTION 5.04. DUE DATES NOT ON BUSINESS DAYS. If payment required hereunder
    becomes due on a date that is not a Business Day, then such due date shall
    be deemed to be the next following Business Day.

SECTION 5.05. RIGHT TO PREPAY. The Borrower shall have the right, in its sole
    discretion, to prepay, in whole or in part, the Outstanding Principal
    Balance at any time, without any penalty.

                                   ARTICLE VI

                                     SET-OFF

SECTION 6.01. GRANT OF A RIGHT OF SETOFF. In the case of an Event of Default,
    the Borrower hereby grants the Lender a right of set-off on all Revenue
    Splits to be made by Lender to the Borrower under the Services Agreement
    against all payments to be made by the Borrower to the Lender under this
    Agreement, to the extent permitted under the laws of France. The Lender may
    withhold such Revenue Splits and apply them in the manner provided in
    Section 7.02(c) hereof.

                                  ARTICLE VII

                                    COVENANTS

SECTION 7.01. AFFIRMATIVE COVENANTS. During the term of this Agreement, the
    Borrower covenants and agrees:

(a) CORPORATE EXISTENCE AND AUTHORIZATIONS. The Borrower shall maintain in good
    standing its corporate existence and its right to transact business in those
    jurisdictions in which it is now or hereafter doing a material amount of
    business, and the Borrower shall maintain all material licenses, permits and
    registrations necessary for the conduct of its operations.

(b) COMPLIANCE WITH LAWS. The Borrower shall comply with all material Laws
    applicable to its business operations.

(c) PAYMENT OF OBLIGATIONS. The Borrower shall promptly pay and discharge or
    cause to be paid and discharged, as and when due (or as amended or extended
    by the lender or creditor), any and all of its lawful debts and other
    obligations, including all lawful taxes, rates, levies and assessments and
    all claims for labor, materials or supplies; provided, however, that nothing
    herein contained shall be construed as prohibiting the Borrower from
    diligently contesting in good faith by appropriate

                                       4
<Page>

    proceedings the validity of any such debt or other obligation, provided
    Borrower has established adequate reserves for such debt or obligation on
    its books and records.

(d) FINANCIAL INFORMATION. The Borrower will provide the Lender with copies of
    its audited financial statements for the year ending December 31, 2001 as
    soon as reasonably practicable after such financial statements are
    available, but in no event later than March 31, 2002. The Borrower will
    provide the Lender with unaudited quarterly financial statements within 45
    days of the end of each calendar quarter ending during prior to the Maturity
    Date.

SECTION 7.02. NEGATIVE COVENANTS. During the term of this Agreement, the
    Borrower covenants and agrees, that without the prior written consent of the
    Lender:

(a) DIVIDENDS. The Borrower shall not declare or pay dividends or other
    distributions to its existing shareholders or other equity owners.

(b) USE OF PROCEEDS. The Borrower will not use the proceeds of the Loan to be
    used for any purpose other than that stated herein.

(c) CONFLICTING AGREEMENTS. The Borrower will not enter into any agreement, any
    term or condition of which would, if complied with by Borrower, result in an
    Event of Default.

                                  ARTICLE VIII

                                     DEFAULT

SECTION 8.01. EVENTS OF DEFAULT. Any one or more of the following shall
    constitute an Event of Default under this Agreement, unless waived by the
    Lender:

(a) PAYMENT. Failure to pay principal or interest when due and payable under the
    Note, or failure to pay any other indebtedness of the Borrower which
    continues beyond any applicable grace period.

(b) BREACH OF COVENANTS. The material breach of any covenant in Article VI
    unless expressly waived, in writing, by the Lender, which breach is not
    cured within 30 Business Days.

(c) ACCELERATION OF OTHER INDEBTEDNESS. Any obligation of the Borrower for the
    payment of borrowed money becomes or is declared to be due and payable or
    required to be prepaid (other than by a regularly scheduled prepayment)
    prior to the expressed maturity thereof and the Borrower has not cured the
    default giving rise to such an acceleration within 30 Business Days.

(d) JUDGMENTS; ATTACHMENT; ETC. Any one or more judgments or orders against the
    Borrower or any attachment or other levy against the property of the
    Borrower with respect to a claim or claims, involving in the aggregate
    liabilities (not paid or fully covered by insurance, less the amount of
    reasonable deductibles) in excess of $500,000, remains unpaid, unstayed on
    appeal, undischarged, unbonded or undismissed for a period of 30 Business
    Days.

SECTION 8.02. RIGHTS AND REMEDIES IN THE EVENT OF DEFAULT.

(a) Upon any Event of Default, and at any time thereafter, the Lender may
    declare in writing to the Borrower all or any part of the Outstanding
    Principal Balance and accrued interest thereon

                                       5
<Page>

    immediately due and payable, and upon such declaration the then Outstanding
    Principal Balance and such accrued interest shall automatically become
    immediately due and payable.

(b) Set-off against all amounts owed by the Borrower to the Lender under this
    Agreement and the Note, any and all payments which may be due from Lender to
    Borrower under the Services Agreement.

(c) Any funds received by the Lender with respect to the Loan shall be applied
    as follows: (i) first, to the payment of the reasonable and necessary
    expenses incurred by Lender in connection with the collection of amounts due
    hereunder; (ii) second, to the payment of interest accrued and unpaid on the
    Loan; and (iii) third, to the payment of Outstanding Principal Balance. Any
    remaining amounts shall be paid to the Borrower.

(d) At the option of the Lenders, the Borrower shall pay interest on (i) all
    amounts overdue by more than five Business Days and (ii) all amounts due by
    the Borrower, whether mature or not, after the occurrence of an Event of
    Default (until such time as the Event of Default may be cured), at a rate
    equal to the greater of (x) 7.0% per annum or (y) the prime interest rate
    prevailing in the United States as of the date of the Event of Default, as
    published in the WALL STREET JOURNAL.

SECTION 8.03. REMEDIES NOT EXCLUSIVE. The Lender shall be entitled to enforce
    payment and performance of all obligations of the Borrower hereunder or
    under the Note and to exercise all rights and powers hereunder or under the
    Note, or under any Law and the pursuit of any remedy available to the Lender
    against the Borrower shall not prejudice or in any manner affect the
    Lender's right to realize upon or enforce any other remedy or security now
    or hereafter available to it in such order and in such manner as the Lender
    may determine in its sole discretion. No such right or remedy shall be
    exclusive, but each shall be cumulative and shall be in addition to every
    other remedy provided herein or in any other agreement or by Law and each
    such remedy may be exercised concurrently or independently. Nothing in this
    Agreement shall be construed as prohibiting the Lender from seeking a
    deficiency judgment against the Borrower.

                                   ARTICLE IX

                                  MISCELLANEOUS

SECTION 9.01. NOTICES. All notices or other communications to be given hereunder
    shall be given in writing and delivered by (a) certified mail, return
    receipt requested, (b) personal delivery, (c) facsimile or (d) express
    carrier addressed as follows:

If to the Lender:                   Transgenomic, Inc.
                                    12325 Emmet Street
                                    Omaha, Nebraska 68164
                                    U.S.A.
                                    Attention: Gregory J. Duman
                                    Email:  gduman@transgenomic.com
                                    Telephone: (402) 452-5400
                                    Telecopy: (402) 452-5447

If to the Borrower:                 Genodyssee S.A.
                                    Parc Affaires Technopolis
                                    3, avenue du Canada - Batiment Alpha
                                    BP 810 Les Ulis - 91974 Courtaboeuf Cedex
                                    France

                                       6
<Page>

                                    Attention: Jean-Louis Escary
                                    Email: escary@genodyssee.com
                                    Telephone: (33)(0) 1 69 29 80 55
                                    Telecopy: (33)(0) 1 69 29 80 79

or to such other address furnished by any party to the other in writing at any
time and from time to time for such notice purposes. Any notice served by either
party on the other shall be deemed effective upon receipt of return receipt if
sent by certified mail, return receipt requested, when received, if delivered
personally, upon machine confirmation if sent by facsimile, or upon confirmation
of delivery by an express carrier.

SECTION 9.02. AMENDMENTS AND WAIVERS. No amendment, modification or waiver of
    any provision of this Agreement or the Note shall be effective unless the
    same shall be in writing and signed by the Borrower and the Lender;
    provided, however, that any such waiver or consent shall be effective only
    in the specific instance and for the purpose for which given.

SECTION 9.03. SUCCESSORS AND ASSIGNS. Neither the Borrower nor the Lender may
    assign, delegate or transfer any of its rights or obligations under this
    Agreement or the Note without the prior written consent of the other.

SECTION 9.04. SEVERABILITY. If any provision of this Agreement is held invalid
    or unenforceable, or which is prohibited under Law for any reason, the
    invalidity shall not affect the validity of the remaining provisions of this
    Agreement, and the parties shall substitute for the invalid provision a
    valid provision which most closely approximates the intent and economic
    effect of the invalid provision.

SECTION 9.05. COUNTERPARTS. This Agreement may be executed by the parties hereto
    on any number of separate counterparts, and all such counterparts taken
    together shall constitute one and the same instrument. It shall not be
    necessary in making proof of this Agreement to produce or account for more
    than one counterpart signed by the party to be charged.

SECTION 9.06. GOVERNING LAW; ARBITRATION; NO THIRD-PARTY RIGHTS.

     (a) This Agreement and the rights and obligations of the parties
hereunder shall be governed by and construed and interpreted in accordance with
the laws of the United States and State of New York applicable to contracts made
and to be performed wholly within such State, without regard to any choice or
conflict of laws rules.

     (b) The parties to this Agreement shall act in good faith to resolve
any dispute or other controversy arising under this Agreement. Absent agreement
resolving a dispute within 20 days after written notice of the dispute has been
delivered from one party to the other, any party shall have the right to seek to
settle the matter by arbitration to the exclusion of any other form of dispute
resolution. Any arbitration shall be conducted according to the applicable rules
of the American Arbitration Association and shall take place in New York, New
York. Such arbitration shall be heard by a single arbitrator, who shall be
jointly designated by the Lender and the Borrower if the parties are unable to
agree within ten (10) days after the dispute is submitted to arbitration, by the
American Arbitration Association. The decision of the arbitrator shall be final
and binding upon the parties hereto. The each party in any arbitration
proceeding shall pay its own costs in connection therewith, including attorneys'
fees.

     (c) This Agreement is solely for the benefit of the parties hereto and
their respective successors and assigns, and no other Person shall have any
right, benefit, priority or interest under, or because of the existence of, this
Agreement.

                                       7
<Page>

SECTION 9.07. HEADINGS. The section headings are for convenience only and shall
    not affect the interpretation or construction of this Agreement or the Note.
    The Exhibits referred to throughout this Agreement are attached to this
    Agreement and are incorporated into this Agreement. Unless the context
    clearly indicates, words used in the singular include the plural, words in
    the plural include the singular and the word "including" means "including
    but not limited to."

SECTION 9.08. THE LENDER'S SOLE DISCRETION. Any provision in any of this
    Agreement or the Note which requires the Lender's approval or consent shall
    be interpreted to mean at the Lender's sole discretion unless otherwise
    specified.

SECTION 9.09. CONFLICT OF TERMS. In the event of any material conflict between
    the terms of this Agreement and the Note, the terms of this Agreement shall
    control.

SECTION 9.10. OTHER JURISDICTIONS. The Borrower agrees that the Lender shall
    have the right to proceed against the Borrower or its property in a court in
    any location to enable the Lender to enforce a judgment or other court order
    entered in favor of the Lender. The Borrower waives any objection that it
    may have to the location of the court in which the Lender have commenced a
    proceeding described in this Section 8.10.

SECTION 9.11. WAIVER. The failure of either party at any time to require
    performance by the other party of any provision of this Agreement shall not
    affect in any way the full right to require the performance at any
    subsequent time. The waiver by either party of a breach of any provision of
    this Agreement shall not be taken or held to be a waiver of the provision
    itself. Any course of performance shall not be deemed to amend or limit any
    provision of this Agreement.

SECTION 9.12. SECTION REFERENCES. References to "Sections," "subsections" and
    "Exhibits" shall be to Sections, subsections, Exhibits and Schedules,
    respectively, of this Agreement unless otherwise specifically provided.

SECTION 9.13. RELATIONSHIP OF PARTIES. Nothing contained in this Agreement shall
    be deemed or construed by the parties, or by any third party, to create the
    relationship of partnership or joint venture between the parties hereto, it
    being understood and agreed that no provision contained herein shall be
    deemed to create any relationship between the parties hereto other than the
    relationship of borrower and lender.

SECTION 9.14. ENTIRE AGREEMENT. This Agreement and the Note set forth all of the
    promises, agreements, conditions and understandings between the parties
    respecting the subject matter hereof and supersedes all negotiations,
    conversations, discussions, correspondence, memorandums and agreements
    between the parties concerning the subject matter.

SECTION 9.15. TIME OF THE ESSENCE. Time is of the essence with respect to this
    Agreement

                                        8
<Page>

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed
and delivered by their proper and duly authorized officers as of the day and
year first above written.

                                     LENDER

    TRANSGENOMIC, INC., a Delaware corporation

                                      By  /s/ Collin J. D'Silva
                                         --------------------------------------

    Collin J. D'Silva, President and Chief Executive Officer

                                    BORROWER

                                      GENODYSSEE S.A., a French societe anonyme

                                      By  /s/ Jean-Louis Escary
                                         --------------------------------------

    Jean-Louis Escary, President du Conseil d' Administration

                                        9
<Page>

                                    EXHIBIT A

                                 PROMISSORY NOTE

$1,000,000.00                                              Courtaboeuf,, France
December 28, 2001

For value received, the undersigned, GENODYSSEE S.A., a societe anonyme formed
under the laws of France (herein, the "Maker") hereby promises to pay to the
order of TRANSGENOMIC, INC., a corporation formed under the laws of the State of
Delaware, U.S.A. (hereinafter, the "Holder"), at any place designated at any
time by the Holder, in lawful money of the United States of America and in
immediately available funds, the principal sum of ONE MILLION AND 00/100 DOLLARS
($1,000,000.00) or, if less, the then unpaid principal amount of all Advances
(as defined in that certain Revolving Line of Credit Agreement, dated December
28, 2001, between the Maker and the Holder (the "Loan Agreement")) made by the
Holder pursuant to the Agreement. (the "Principal Balance") on or before
December 31, 2004.

This Note is issued pursuant to the Loan Agreement. All capitalized terms used
and not otherwise defined shall have the meanings given them in the Loan
Agreement.

The Maker promises to pay the Principal Balance as set forth in the Loan
Agreement. The Maker further promises to pay interest from the date hereof on
the outstanding Principal Balance at the rate set forth in the Loan Agreement.
Interest shall be computed and payable as provided in the Loan Agreement.

Upon any Event of Default, the Holder may, without notice or demand, declare the
then outstanding Principal Balance and all outstanding interest immediately due
and payable and shall then have in any jurisdiction where enforcement hereof is
sought, in addition to any other rights or remedies, the rights and remedies set
forth in the Loan Agreement.

If this Note is not paid as provided herein and in the Loan Agreement and is
referred to an attorney for collection, the Maker promises to pay the reasonable
fees and expenses of such attorney in addition to the full amount due hereon,
whether or not litigation is commenced.

Demand for payment, protest, notice of dishonor and all other notices and
demands under this Note and any and all lack of diligence in the enforcement of
this Note are hereby waived by the Maker, and the same hereby assents to each
and every extension or postponement of the time of payment, at or after demand,
or other indulgence, and hereby waive any and all notice thereof.

No amendment, modification or waiver of any provision of this Note, nor consent
to any departure by the Maker here from, shall be effective unless the same
shall be in a writing signed by an authorized officer of the Holder, and then
only in the specific instance and for the purpose for which given. No failure to
exercise, and no delay in exercising, any right under the Loan Agreement or this
Note shall operate as a waiver thereof, nor shall any single or partial exercise
of any right under the Loan Agreement or this Note preclude any other or further
exercise thereof or the exercise of any other right. Each and every right
granted hereunder or by law or in equity shall be deemed cumulative, and such
remedies may be exercised from time to time concurrently or consecutively.

All notices required to be given or which may be given in connection with this
Note shall be given in the manner required for notices under the Loan Agreement.

Any term of this Note that does not comply with applicable law will not be
effective if that law does not

                                       10
<Page>

expressly or impliedly permit variations by agreement. If any part of this Note
cannot be enforced according to its terms, that fact will not affect the balance
of this Note.

Neither this Note nor the Maker's or Holder's rights and obligations under this
Note are assignable or delegable without the prior written consent of the other
as set forth in the Loan Agreement. This Note will be governed by the laws of
the United States and the State of New York, including the Uniform Commercial
Code. The terms of any agreement securing the payment of this Note may also be
governed by the law of the state where the property is located.

IN WITNESS WHEREOF, the Maker has executed and delivered this Note effective as
of the date first set forth above.
                                      MAKER

                                      GENODYSSEE S.A., a French societe anonyme
                                      By  /s/ Jean-Louis Escary
                                          -------------------------------------

    Jean-Louis Escary, President du Conseil d' Administration

                                       11<Page>

EXHIBIT 10.13

**Certain confidential portions of this Exhibit were omitted by means of
redacting a portion of the text indicated by two asterisks "**". This Exhibit
has been filed separately with the Secretary of the Commission without the **
pursuant to the Registrant's Application Requesting Confidential Treatment
under Rule 24b-2 of the Securities Exchange Act.

                                LICENSE AGREEMENT

     This Agreement, effective this 1st day of December, 1989 by and between
Millipore Corporation, a corporation of the Commonwealth of Massachusetts having
a place of business in Bedford, Massachusetts ("LICENSOR") and Cruachem Holdings
Limited, a corporation of the United Kingdom having a place of business in
Glasgow, Scotland ("LICENSEE").

RECITALS

     LICENSOR is the owner of United States Patent No. 4,725,677, issued
February 16, 1988, entitled "Process for the Preparation of Oligonucleotides"
(the "'677 Patent").

     LICENSEE is desirous of obtaining a license under the '677 Patent, and
LICENSOR is willing to grant such license under the terms and conditions
hereinafter set forth.

     In consideration of the above recitals and the mutual covenants and
obligations set forth herein, the parties agree as follows:
ARTICLE I. DEFINITIONS

     1.1 "Licensed Patent" shall mean the '677 Patent, all reissues,
continuations and extensions thereof, as well as all foreign patents and patent
applications corresponding thereto.

     1.2 "Licensed Product" shall mean any product or process covered by a claim
of any unexpired, issued Licensed Patent which has not been disclaimed,
forfeited or held invalid by a decision beyond the right of review.

     1.3 "Net Sales" means the gross selling price of Licensed Product sold by
LICENSEE less: (i) allowances for damaged and returned goods; (ii) discounts
actually credited to customers; and (iii) sales and excise taxes actually paid
by LICENSEE with respect to the sale of Licensed Product. The Net Sales of
Licensed Product used, but not sold, by LICENSEE shall be calculated as though
such Licensed Product had been sold by LICENSEE during the same time period to a
third party in a "bona fide arms-length transaction. A Licensed Product is
considered sold hereunder when invoiced or, if not invoiced, when shipped or
mailed or otherwise delivered, or when paid for before delivery.

                                        1
<Page>

ARTICLE II. GRANT

     2.1 LICENSOR hereby grants, subject to the terms and conditions herein, to
LICENSEE and LICENSEE hereby accepts a non-exclusive, non-transferable license
under the Licensed Patent to manufacture, use and sell Licensed Product.

     2.2 LICENSEE shall have no right to grant sublicenses under this Agreement.
Notwithstanding the foregoing, LICENSEE shall have a right to grant sub-licenses
under this Agreement to a company which is a subsidiary of or otherwise
controlled by LICENSEE and only upon such terms as are herein contained for the
performance and observance of obligations by LICENSEE, and LICENSEE shall notify
LICENSOR of any such sub-license and provide evidence to LICENSOR of its
subsidiary or controlled status.

ARTICLE III. ROYALTIES AND PAYMENTS

     3.1 In consideration of the rights granted by LICENSOR to LICENSEE under
this Agreement, LICENSEE agrees to pay LICENSOR:

          (a) One-hundred thousand US dollars (US $100,000) payable in
     installments as set forth in Section 3.3 below.

          (b) A royalty of ** of Net Sales of all Licensed Product manufactured,
     used or sold by LICENSEE during the term of this Agreement.

     3.2 LICENSEE shall also pay to LICENSOR in installments at the times
hereinafter provided an amount equal to (CONFIDENTIAL TREATMENT REQUESTED) of
Net Sales of all Licensed Product manufactured, used or sold by LICENSEE (i) in
the United States of America during the period February 16, 1986 through June
30, 1989 and (ii) worldwide during the period July 1, 1989 through November 30,
1989.

     3.3 Each of the installments referred to in Sections 3.l(a) and 3.2 shall
together amount to $15,000 and the first payment shall be made at the time of
execution of this Agreement. Subsequent payments of $15,000 shall be made within
45 days of the last day of February, May, August and November of each year
commencing on February 28, 1990 and continuing until the payments called for in
Sections 3.l(a) and 3.2 are paid in full. The first of such subsequent payments
shall be accompanied by a written accounting of all Licensed Products
manufactured, used or sold (i) in the United States of America for the period
February 16, 1988 through June 30, 1989 and (ii) worldwide for the period July
1, 1989 through November 30, 1989 in sufficient detail to permit a calculation
of the royalties due thereon.

ARTICLE IV. REMITTANCES, RECORDS AND REPORTS

     4.1 Commencing in 1990, LICENSEE agrees to deliver to LICENSOR within
forty-five (45) days of the last day of February, May, August and November of
each year during the term of this Agreement a written accounting of all Licensed
Product used or sold by it during the preceeding three

                                        2
<Page>

months in sufficient detail to permit a calculation of the royalties due
thereon. LICENSEE agrees to accompany such accounting with the payment due
thereon.

     4.2 LICENSEE agrees to maintain adequate records in sufficient detail to
enable the royalties payable by LICENSEE hereunder to be determined. It is
further agreed that LICENSOR shall have the right, at its own expense and during
regular business hours no more than once in any calendar year during the term of
this Agreement and for one (1) year thereafter, to have such records examined by
an independent auditor acceptable to both LICENSOR and LICENSEE.

     4.3 Any payment hereunder which is made more than thirty (30) days past due
sha11 be subject to interest payments calculated from the due date at the prime
rate (i.e., the base rate on corporate 1oans given at large U.S. commercial
banks) plus one percent (1%).

ARTICLE V. MOST FAVORED LICENSEE

     5.1 In the event that LICENSOR shall hereafter grant a license to a third
party under the Licensed Patent at a more favorable royalty rate, LICENSEE shall
have the right to substitute the more favorable royalty rate granted to such
third party, but only if LICENSEE shall accept any less favorable terms that may
be included in such license. Any change in royalty rate hereunder shell be by
written amendment and shall be effective only for the period during which the
more favorable royalty is in effect under such other license.

     5.2 The provisions of Section 5.1 shall not apply where:

          (a) LICENSOR has received, in lieu of or in addition to a cash
royalty, a grant of proprietary rights, a license or immunity from suit, or
other considerations in exchange for such license; or

          (b) A more favorable royalty is given only in consideration of the
settlement of a claim of past infringement and does not apply in respect of
future infringement.

ARTICLE VI. INFRINGEMENT

     6.1 If LICENSEE is charged with a claim of patent infringement through its
sale of Licensed Product by a third party, and such claim substantially
interferes with LICENSEE'S ability to exercise in a commercially reasonable
manner its rights under this Agreement, LICENSEE shall give LICENSOR notice of
such claim. If, after reasonable and diligent defense against such claim,
including conferring with LICENSOR regarding the merits thereof, LICENSEE is
required to obtain a license under the patent

                                        3
<Page>

rights of such third party, LICENSEE may at its election reduce the royalty rate
provided for in Section 3.1(b) by up TO fifty percent (50%), provided that said
reduction shall be by no more than fifty percent (50%) of any royalties paid to
such third party.

     6.2 The provisions of Section 6.1 shall not apply to any claim arising from
U.S. Patent Nos. 4,458,066 and/or 4,415,722, or under any patent rights
(domestic or foreign) issuing from or corresponding to said aforementioned
patents.

ARTICLE VII. PATENT MARKING

     7.1 LICENSEE agrees to mark labels, product literature, and packages for
Licensed Products which are sold with the following legend:

        "This product contains reagents manufactured under patent license from
        Millipore Corporation

        --U.S. Patent No. 4,725,677."

ARTICLE VIII. RESTRICTED WARRANTY AND INDEMNITY; INFRINGEMENT OF LICENSED PATENT
AND MAINTENANCE

     8.1 LICENSOR warrants that it has full authority to enter into this
Agreement and that it has no knowledge of any third party rights that would
affect its ability to grant the license hereunder. However, LICENSOR makes no
representation or warranty, express or implied, as to the validity of the
Licensed Patent nor to the merchantability of Licensed Product that is sold by
LICENSEE. LICENSOR does not assume any liability for any infringement or alleged
infringement of any patent or other rights of third parties due to LICENSEE's
activities under the license set forth herein.

     8.2 LICENSEE agrees to defend, indemnify and hold LICENSOR harmless from
any claims of whatever nature arising from LICENSEE's making, using and/or
selling Licensed Product unless such claims can be established to be based on
LICENSOR's negligence.

     8.3 Should LICENSOR be made aware of any apparent infringement of the
Licensed Patent upon receipt of written notice from LICENSEE to that effect by
any of the following entities: Applied Biosystems, Inc.; Beckman Instruments,
Inc.; Biosearch, Inc.; E.I. DuPont DeNemours & Co., Inc.; Pharmacia LKB
Biotechnology AB; Sigma Chemical Company; Vega Biotechnologies, Inc.; American
Bionetics, Inc., E Merck AG Damstadf; or Glen Research Corporation and any other
person(s) or legal entity, corporate body or otherwise, which is not licensed by
LICENSOR and which LICENSEE states is having a significant effect on its
business in Licensed Product (collectively referred to herein as an

                                        4
<Page>

"unlicensed entity"). LICENSOR shall provide LICENSEE written notice that such
unlicensed entity has either (1) accepted a license, (2) been found not to
infringe the Licensed Patent and the reasons therefor or (3) been contacted
concerning its unlicensed use. In the event of item (3) above, LICENSOR will
commence legal action for infringement against any such unlicensed entity if no
satisfactory response is received within a reasonable period of time or if
discussions become stalled for an unreasonable period of time.

     LICENSOR"S obligation to pursue action against an unlicensed entity shall
only apply if LICENSEE can demonstrate that such unlicensed entity has annual
net sales of Licensed Product which exceed $400,000, provided that if the
unlicensed entity's annual net sales of Licensed Product do not exceed $400,000
and LICENSEE shall insist that LICENSOR take action then the costs of LICENSOR
in taking such action as aforesaid will be paid by LICENSEE. In the event of
LICENSOR being required by LICENSEE to take action against an unlicensed entity
having net sales less than $400,OOO, LICENSOR shall assume full control over
such action or any settlement thereof, and LICENSOR may terminate such action if
LICENSEE fails to pay any invoice for legal expenses within 30 days of receipt
from LICENSOR. LICENSOR shall be obligated to pursue only one infringement
action at a time against an unlicensed entity, in an order to be solely
determined by LICENSOR.

     8.4 LICENSOR will use its reasonable best efforts to ensure that all
registrations of the Licensed Patent are maintained in full force and effect to
protect the interests hereunder of LICENSEE.

ARTICLE IX.  TERM AND TERMINATION

     9.1 Unless earlier terminated as provided in this Article IX, this
Agreement shall continue in full force and effect until February 16, 2005.

     9.2 LICENSEE shall have the right to terminate this Agreement and surrender
the license granted hereunder at any time upon ninety (90) days written notice
to LICENSOR.

     9.3 If LICENSEE defaults in the performance of any of the obligations under
this Agreement including the failure to make any of the payments provided for in
Article III at the times specified therein and such default is not cured within
thirty (30) days after LICENSOR has given to LICENSEE written notice specifying
the nature of the default, LICENSOR shall have the right to terminate this
Agreement by giving written notice of termination to LICENSEE. Upon the receipt
of such notice of termination by LICENSEE this Agreement shall immediately
terminate.

     9.4 If during the term of this Agreement, LICENSEE becomes bankrupt or
insolvent, or if the business of LICENSEE is placed in the hands of a receiver
or trustee, whether by voluntary act of LICENSEE or otherwise, this Agreement
shall immediately terminate.

                                        5
<Page>

     9.5 The termination of this Agreement for any reason shall be without
prejudice to LICENSOR's right to receive all payments accrued and unpaid at the
effective date of such termination and to the remedy of either party hereto with
respect to any previous breach or default in respect to any of the covenants
contained herein.

ARTICLE X.  NOTICE

     10.1 Any notice or other communication relating to this Agreement shall be
sent by registered mail or overnight express prepaid to the address of the party
to be served therewith which is shown below and shall be deemed to have been
given upon the date the notice or communication was mailed:

     If to LICENSOR:                    Millipore Corporation
                                        80 Ashby Road
                                        Bedford, Massachusetts 01730
                                        Attention: General Counsel

     If to LICENSEE:                    Cruachem Holdings Limited
                                        Todd Campus
                                        West of Scotland Science Park
                                        Acre Road
                                        Glasgow G20 OVA
                                        Scotland

ARTICLE XI. RIGHT OF ASSIGNMENT

     11.1 Neither this Agreement nor any of the rights and powers created herein
may be assigned, in whole or in part, by either party hereto, without the
written consent of the other party and any attempted assignment or transfer
thereof without such consent shall be void, except that without securing such
prior written consent, either party may assign this Agreement to a successor of
all or substantially all of the business and good will in Licensed Patent or
Licensed Product by giving the other party thirty (30) days written notice
thereof.

ARTICLE XII. GENERAL PROVISIONS

     12.1 This Agreement is binding upon and inures to the benefit of the
parties hereto. This Agreement and the license granted herein is personal to
LICENSEE and cannot be assigned or transferred by LICENSEE except as provided
for in Article XI.

                                        6
<Page>

     12.2 This Agreement is to be construed under the laws of the Commonwealth
of Massachusetts.

     12.3 This Agreement constitutes the entire agreement between the parties
hereto and there are no representations or warranties of any kind not expressly
set forth herein. No modification, amendment or waiver of any of its provisions
shall have any force or effect unless it be in writing and signed by the parties
to be bound thereby.

     12.4 This Agreement has been drafted on the basis of mutual understanding
and neither party shall be prejudiced as the draftor thereof.

     12.5 The waiver by either LICENSOR or LICENSEE of any right or failure to
perform or of any breach by the other shall not be deemed as a waiver of any
other right hereunder or of any other breach of failure by the other, whether of
a similar nature or otherwise.

     12.6 If any provision of this Agreement shall be held to be invalid,
illegal, or unenforceable, the validity, legality and enforceability of the
remaining provisions shall not in any way be affected or impaired thereby.

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
signed in duplicate counterparts in their behalf by an authorized representative
as of the date and year first above written.

        MILLIPORE CORPORATION           CRUACHEM HOLDINGS LIMITED
           (LICENSOR)                           (LICENSEE)

        By /s/ [ILLEGIBLE]                By /s/ Ian Wilke
           --------------------------        -------------------------------
        Title President                   Title Chief Executive
              -----------------------           ----------------------------
              Millipore-Bioresearch
               Division

                                        7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}]]